Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares IssuedShares OutstandingShares Outstanding
Ratios

Voyager Therapeutics (VYGR) Accumulated Depreciation & Amortization (2016 - 2025)

Voyager Therapeutics' Accumulated Depreciation & Amortization history spans 12 years, with the latest figure at $19.2 million for Q4 2025.

  • On a quarterly basis, Accumulated Depreciation & Amortization rose 20.01% to $19.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was $19.2 million, a 20.01% increase, with the full-year FY2025 number at $19.2 million, up 20.01% from a year prior.
  • Accumulated Depreciation & Amortization hit $19.2 million in Q4 2025 for Voyager Therapeutics, up from $16.0 million in the prior quarter.
  • Over the last five years, Accumulated Depreciation & Amortization for VYGR hit a ceiling of $19.2 million in Q4 2025 and a floor of $15.0 million in Q4 2023.
  • Historically, Accumulated Depreciation & Amortization has averaged $16.7 million across 5 years, with a median of $16.0 million in 2024.
  • Biggest five-year swings in Accumulated Depreciation & Amortization: soared 37.54% in 2021 and later fell 12.61% in 2023.
  • Tracing VYGR's Accumulated Depreciation & Amortization over 5 years: stood at $15.9 million in 2021, then grew by 8.13% to $17.2 million in 2022, then decreased by 12.61% to $15.0 million in 2023, then increased by 6.12% to $16.0 million in 2024, then rose by 20.01% to $19.2 million in 2025.
  • Business Quant data shows Accumulated Depreciation & Amortization for VYGR at $19.2 million in Q4 2025, $16.0 million in Q4 2024, and $15.0 million in Q4 2023.